Adamis Pharmaceuticals Provides Update on First Quarter 2021 Financial Results Conference Call

Rhea-AI Summary

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has postponed its investor conference call originally set for May 17, 2021, due to a delay in filing its Quarterly Report (Form 10-Q) for Q1 2021. The company filed a Form 12b-25 with the SEC to extend the filing deadline by five days, as allowed under Rule 12b-25 of the Securities Exchange Act of 1934. A new date for the conference call will be announced soon. Adamis focuses on developing biopharmaceutical products for various therapeutic areas, including allergy and respiratory diseases.

Positive

• Development of SYMJEPI® approved for allergic reactions.
• Focus on various therapeutic products, including opioid overdose and respiratory diseases.

Negative

• Delay in filing Quarterly Report (Form 10-Q) may indicate internal issues.
• Postponement of investor conference call could raise investor concerns.

SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it is postponing its previously announced investor conference call scheduled to be held on Monday, May 17, 2021, at 2 p.m. Pacific Time. The company filed a Form 12b-25 with the Securities and Exchange Commission today in order to extend the due date of its Quarterly Report on Form 10-Q for the three months ended March 31, 2021, by five calendar days as permitted by Rule 12b-25 under the Securities Exchange Act of 1934, and is postponing the investor call in light of that filing delay. The company will announce a new date and time for a rescheduled investor call.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company’s SYMJEPI^® (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. In addition to its naloxone injection product candidate, ZIMHI™, Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma and COPD. The company’s subsidiary, US Compounding Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. For additional information about Adamis Pharmaceuticals, please visit www.adamispharmaceuticals.com.  

Contact:

Adamis Investor Relations
Robert Uhl
Managing Director
Westwicke ICR
619.228.5886
robert.uhl@westwicke.com  

 

FAQ

Why was the May 17, 2021 investor conference call for ADMP postponed?

The call was postponed due to a delay in filing the Quarterly Report (Form 10-Q) for Q1 2021.

What is the new date for the ADMP investor conference call?

A new date for the investor conference call will be announced soon.

What products does Adamis Pharmaceuticals focus on?

Adamis focuses on developing products for allergy, opioid overdose, and respiratory diseases.

What is the significance of the Form 12b-25 filing for ADMP?

The Form 12b-25 filing allows Adamis to extend the due date for its Quarterly Report by five calendar days.

What are the potential implications of the ADMP filing delay?

The filing delay may raise concerns about the company's financial reporting and internal processes.